Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-90 M5A Radioimmunotherapy for Colorectal Liver Metastases
NCT01320683Phase 2Terminated
- Sponsor
- City of Hope
- Start
- Mar 2011
- Primary completion
- Dec 2014
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90-DOTA-M5A in colorectal cancer (CRC), liver metastases, sponsored by City of Hope. Started Mar 2011; status: terminated.
02
Drugs
yttrium-90-DOTA-M5A
03
Conditions
colorectal cancer (CRC)liver metastases
Beyond the preview
Go deeper on NCT01320683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01320683.